Your browser doesn't support javascript.
loading
The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy.
Ahmadpour, Sajjad; Habibi, Mohammad Amin; Ghazi, Farzaneh Sadat; Molazadeh, Mikaeil; Pashaie, Mohammad Reza; Mohammadpour, Yousef.
Afiliación
  • Ahmadpour S; Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran.
  • Habibi MA; Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Ghazi FS; Student Research Committee, Qom University of Medical Sciences, Qom, Iran.
  • Molazadeh M; Department of Medical Physics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Pashaie MR; Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran; Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
  • Mohammadpour Y; Department of Medical Education, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. Electronic address: mohammadpour.yousef@gmail.com.
Cancer Treat Res Commun ; 40: 100823, 2024.
Article en En | MEDLINE | ID: mdl-38875884
ABSTRACT
Tumors can produce bioactive substances called tumor-derived supernatants (TDS) that modify the immune response in the host body. This can result in immunosuppressive effects that promote the growth and spread of cancer. During tumorigenesis, the exudation of these substances can disrupt the function of immune sentinels in the host and reinforce the support for cancer cell growth. Tumor cells produce cytokines, growth factors, and proteins, which contribute to the progression of the tumor and the formation of premetastatic niches. By understanding how cancer cells influence the host immune system through the secretion of these factors, we can gain new insights into cancer diagnosis and therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Progresión de la Enfermedad / Carcinogénesis / Inmunoterapia / Neoplasias Límite: Animals / Humans Idioma: En Revista: Cancer Treat Res Commun Año: 2024 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Progresión de la Enfermedad / Carcinogénesis / Inmunoterapia / Neoplasias Límite: Animals / Humans Idioma: En Revista: Cancer Treat Res Commun Año: 2024 Tipo del documento: Article País de afiliación: Irán